China Universal Asset Management Company’s Ovid Therapeutics OVID Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-13,650
Closed -$16.1K – 516
2024
Q3
$16.1K Buy
13,650
+5,315
+64% +$5.55K ﹤0.01% 411
2024
Q2
$6.41K Sell
8,335
-5,244
-39% -$14.6K ﹤0.01% 405
2024
Q1
$41.4K Buy
13,579
+5,401
+66% +$18.1K 0.01% 418
2023
Q4
$26.3K Buy
+8,178
New +$28K 0.01% 406
2022
Q4
– Sell
-660
Closed -$1K – 439
2022
Q3
$1K Buy
+660
New +$1.38K ﹤0.01% 406

Other funds holding OVID

China Universal Asset Management Company's OVID Position: Q4 2024 in Review

China Universal Asset Management Company sold out of Ovid Therapeutics (OVID) in Q4 2024, closing a stake of 13,650 shares — an estimated $16.1K sold.

China Universal Asset Management Company first reported a position in OVID in Q3 2022 and held it in 5 quarters. The position peaked at $41.4K in Q1 2024. 82 funds tracked by Wall St. Rank hold OVID as of Q4 2024.

  • China Universal Asset Management Company reported no remaining Ovid Therapeutics position as of Q4 2024 after selling out during the quarter.
  • China Universal Asset Management Company sold 13,650 Ovid Therapeutics shares in Q4 2024, an estimated $16.1K.
  • China Universal Asset Management Company first reported a position in Ovid Therapeutics in Q3 2022 and held it in 5 quarters.
  • China Universal Asset Management Company's Ovid Therapeutics position peaked at $41.4K in Q1 2024.
  • 82 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2024.

Based on China Universal Asset Management Company's 13F filing for Q4 2024, filed 24 Jan 2025.